ARTICLE | Distillery Therapeutics
Inhibiting ACOX1 for obesity
May 31, 2024 11:29 PM UTC
Inhibiting the peroxisomal β-oxidation enzyme ACOX1 could help treat obesity by increasing serum levels of the very-long-chain fatty acid tetracosahexaenoic acid, which activates the free fatty acid receptor GPR120, thus promoting white adipose tissue browning, mitochondrial biogenesis, and glucose uptake, while also increasing lean mass.
In bioinformatic analyses of public data sets, ACOX1 mRNA expression was higher in livers from obese patients than from non-obese individuals. ...
BCIQ Company Profiles
BCIQ Target Profiles